본문 바로가기
KERD
논문KCI 등재

Panel of Genetic Variations as a Potential Non-invasive Biomarker for Early Diagnosis of Alzheimer’s Disease

Suk Ling Ma|Linda Chiu Wa Lam
대한정신약물학회 (Korean College of Neuropsychopharmacology)|2011.08|Clinical Psychopharmacology and Neuroscience|제9권 제2호|pp. 54-66

2

조회

0

다운로드

3

인용

0

참고문헌

키워드

Alzheimer diseaseDiagnosisGeneticsBiomarkers

초록

Alzheimer’s disease (AD) is the most prevalent form of dementia. Biomarkers such as levels of amyloid beta (Aβ) in cerebrospinal fluid and ApoE genotyping were suggested for the diagnosis of AD, however, the result is either non-conclusive or with invasive procedure. Genome-wide association studies (GWASs) for AD suggested single nucleotide polymorphisms (SNPs) in many genes are associated with the risk of AD, but each only contributed with small effect to the disease. By incorporating a panel of established genetic susceptibility factors, the risk of an individual in getting AD could be better estimated. Further research will be required to reveal if adding to the current well-developed clinical diagnosis protocol, the accuracy and specificity of diagnosis of AD would be greatly improved and if this might also be beneficial in identifying pre-symptomatic AD patients for early diagnosis and intervention of the disease.

Abstract

Alzheimer’s disease (AD) is the most prevalent form of dementia. Biomarkers such as levels of amyloid beta (Aβ) in cerebrospinal fluid and ApoE genotyping were suggested for the diagnosis of AD, however, the result is either non-conclusive or with invasive procedure. Genome-wide association studies (GWASs) for AD suggested single nucleotide polymorphisms (SNPs) in many genes are associated with the risk of AD, but each only contributed with small effect to the disease. By incorporating a panel of established genetic susceptibility factors, the risk of an individual in getting AD could be better estimated. Further research will be required to reveal if adding to the current well-developed clinical diagnosis protocol, the accuracy and specificity of diagnosis of AD would be greatly improved and if this might also be beneficial in identifying pre-symptomatic AD patients for early diagnosis and intervention of the disease.

참고문헌 (194)

  1. Alzheimer's Disease International World Alzheimer Report 2009, "Ferri CP", Alzheimer's Disease International, ~ (2009)
  2. Petersen RC, "Mild cognitive impairment as a diagnostic entity", J Intern Med, 256, pp.183~194 (2004)
  3. Petersen RC, "Mild cognitive impairment: clinical characterization and outcome", Arch Neurol, 56, pp.303~308 (1999)
  4. Petersen RC, "Practice parameter: early detection of dementia: mild cognitive impairment (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology", Neurology, 56, pp.1133~1142 (2001)
  5. Perrin RJ, "Multimodal techniques for diagnosis and prognosis of Alzheimer's disease", Nature, 461, pp.916~922 (2009)
  6. Bird TD, "Genetic aspects of Alzheimer disease", Genet Med, 10, pp.231~239 (2008)
  7. McKhann G, "Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease", Neurology, 34, pp.939~944 (1984)
  8. Lopez OL, "Reliability of NINCDSADRDA clinical criteria for the diagnosis of Alzheimer's disease", Neurology, 40, pp.1517~1522 (1990)
  9. Schofield PW, "Consistency of clinical diagnosis in a community-based longitudinal study of dementia and Alzheimer's disease", Neurology, 42, pp.2159~2164 (1995)
  10. Andreasen N, "Sensitivity, specificity, and stability of CSF-tau in AD in a community-based patient sample", Neurology, 53, pp.1488~1494 (1999)
  11. Arai H, "Tau in cerebrospinal fluid: a potential diagnostic marker in Alzheimer's disease", Ann Neurol, 38, pp.649~652 (1995)
  12. Blennow K, "CSF total tau, Abeta42 and phosphorylated tau protein as biomarkers for Alzheimer's disease", Mol Neurobiol, 24, pp.87~97 (2001)
  13. Galasko D, "CSF tau and Abeta42: logical biomarkers for Alzheimer's disease", Neurobiol Aging, 19, pp.117~119 (1998)
  14. Sunderland T, "Decreased beta-amyloid1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease", JAMA, 289, pp.2094~2103 (2003)
  15. Grunberg J, "Alzheimer's disease associated presenilin-1 holoprotein and its 18-20 kDa C-terminal fragment are death substrates for proteases of the caspase family", Biochemistry, 37, pp.2263~2270 (1998)
  16. Motter R, "Reduction of betaamyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer's disease", Ann Neurol, 38, pp.643~648 (1995)
  17. Olsson A, "Simultaneous measurement of beta-amyloid (1-42), total tau, and phosphorylated tau (Thr181) in cerebrospinal fluid by the xMAP technology", Clin Chem, 51, pp.336~345 (2005)
  18. Vanderstichele H, "Analytical performance and clinical utility of the INNOTEST PHOSPHO-TAU (181P) assay for discrimination between Alzheimer's disease and dementia with Lewy bodies", Clin Chem Lab Med, 44, pp.1472~1480 (2006)
  19. Blennow K, "Cerebrospinal fluid protein biomarkers for Alzheimer's disease", NeuroRx, 1, pp.213~225 (2004)
  20. Green AJ, "Increased tau in the cerebrospinal fluid of patients with frontotemporal dementia and Alzheimer's disease", Neurosci Lett, 259, pp.133~135 (1999)
  21. Kohnken R, "Detection of tau phosphorylated at threonine 231 in cerebrospinal fluid of Alzheimer's disease patients", Neurosci Lett, 287, pp.187~190 (2000)
  22. Hampel H, "Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer disease: a comparative cerebrospinal fluid study", Arch Gen Psychiatry, 61, pp.95~102 (2004)
  23. "Consensus report of the Working Group on: Molecular and Biochemical Markers of Alzheimer's Disease", Neurobiol Aging, 19, pp.109~116 (1998), The Ronald and Nancy Reagan Research Institute of the Alzheimer's Association and the National Institute on Aging Working Group
  24. Vemuri P, "MRI and CSF biomarkers in normal, MCI, and AD subjects: predicting future clinical change", Neurology, 73, pp.294~301 (2009)
  25. Whitwell JL, "MRI correlates of neurofibrillary tangle pathology at autopsy: a voxel-based morphometry study", Neurology, 71, pp.743~749 (2008)
  26. Thompson PM, "Dynamics of gray matter loss in Alzheimer's disease", J Neurosci, 23, pp.994~1005 (2003)
  27. Scahill RI, "Mapping the evolution of regional atrophy in Alzheimer's disease: unbiased analysis of fluid-registered serial MRI", Proc Natl Acad Sci USA, 99, pp.4703~4707 (2002)
  28. Adalsteinsson E, "Longitudinal decline of the neuronal marker N-acetyl aspartate in Alzheimer's disease", Lancet, 355, pp.1696~1697 (2000)
  29. Klunk WE, "Imaging brain amyloid in Alzheimer'sdisease with Pittsburgh Compound-B", Ann Neurol, 55, pp.306~319 (2004)
  30. Jack CR Jr, "11C PiB and structural MRI provide complementary information in imaging of Alzheimer'sdisease and amnestic mild cognitive impairment", Brain, 131, pp.665~680 (2008)
  31. Villemagne VL, "Abeta deposits in older non-demented individuals with cognitive decline are indicative of preclinical Alzheimer's disease", Neuropsychologia, 46, pp.1688~1697 (2008)
  32. Poirier J, "Apolipoprotein E polymorphism and Alzheimer's disease", Lancet, 342, pp.697~699 (1993)
  33. Bertram L, "Systematic meta-analyses of Alzheimer disease genetic association studies: the AlzGene database", Nat Genet, 39, pp.17~23 (2007)
  34. Corder EH, "Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families", Science, 261, pp.921~923 (1993)
  35. Pericak-Vance MA, "Linkage studies in familial Alzheimer disease: evidence for chromosome 19 linkage", Am J Hum Genet, 48, pp.1034~1050 (1991)
  36. Blacker D, "Results of a high-resolution genome screen of 437 Alzheimer's disease families", Hum Mol Genet, 12, pp.23~32 (2003)
  37. Wijsman EM, "Evidence for a novel late-onset Alzheimer disease locus on chromosome 19 p13.2", Am J Hum Genet, 75, pp.394~409 (2004)
  38. Lee JH, "Fine mapping of 10q and 18q for familial Alzheimer's disease in Caribbean Hispanics", Mol Psychiatry, 9, pp.1042~1051 (2004)
  39. Hiltunen M, "Genome-wide linkage disequilibrium mapping of late-onset Alzheimer's disease in Finland", Neurology, 57, pp.1663~1668 (2001)
  40. Zubenko GS, "A genome survey for novel Alzheimer disease risk loci: results at 10-cM resolution", Genomics, 50, pp.121~128 (1998)
  41. Pericak-Vance MA, "Complete genomic screenin late-onset familial Alzheimer disease. Evidence for a new locus on chromosome 12", JAMA, 278, pp.1237~1241 (1997)
  42. Mayeux R, "Chromosome-12 mapping of late-onset Alzheimer disease among Caribbean Hispanics", Am J Hum Genet, 70, pp.237~243 (2002)
  43. Collins JS, "Association of a haplotype for tumor necrosis factor in siblings with late-onset Alzheimer disease: the NIMH Alzheimer Disease Genetics Initiative", Am J Med Genet, 96, pp.823~830 (2000)
  44. Di Bona D, "Systematic review by meta-analyses on the possible role of TNF-alpha polymorphisms in association with Alzheimer's disease", Brain Res Rev, 61, pp.60~68 (2009)
  45. Laws SM, "TNF polymorphisms in Alzheimer disease and functional implications on CSF beta-amyloid levels", Hum Mutat, 26, pp.29~35 (2005)
  46. Ma SL, "Association between tumor necrosis factor-alpha promoter polymorphism and Alzheimer's disease", Neurology, 62, pp.307~309 (2004)
  47. Ramos EM, "Tumor necrosis factor alpha and interleukin 10 promoter region polymorphisms and risk of late-onset Alzheimer disease", Arch Neurol, 63, pp.1165~1169 (2006)
  48. International HapMap Consortium, "The international Hap- Map project", Nature, 426, pp.789~796 (2003)
  49. McCarthy MI, "Genome-wide association studies for complex traits: consensus, uncertainty and challenges", Nat Rev Genet, 9, pp.356~369 (2008)
  50. Harold D, "Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease", Nat Genet, 41, pp.1088~1093 (2009)
  51. Lambert JC, "Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease", Nat Genet, 41, pp.1094~1099 (2009)
  52. Meyer JM, "Multiple threshold model for the onset of Alzheimer's disease in the NAS-NRC twin panel", Am J Med Genet, 81, pp.92~97 (1998)
  53. 김경아, "Biological, clinical and population relevance of 95 loci for blood lipids", NATURE, 466(7307), pp.707~713, NATURE PUBLISHING GROUP
  54. Siest G, "Apolipoprotein E: an important gene and protein to follow in laboratory medicine", Clin Chem, 41, pp.1068~1086 (1995)
  55. Gomez-Isla T, "Clinical and pathological correlates of apolipoprotein E epsilon 4 in Alzheimer's disease", Ann Neurol, 39, pp.62~70 (1996)
  56. Holmes C, "Apolipoprotein E: non-cognitive symptoms and cognitive decline in late onset Alzheimer's disease", J Neurol Neurosurg Psychiatry, 61, pp.580~583 (1996)
  57. Hyman BT, "Epidemiological, clinical, and neuropathological study of apolipoprotein E genotype in Alzheimer's disease", Ann N Y Acad Sci, 802, pp.1~5 (1996)
  58. Kurz A, "Apolipoprotein E type 4 allele and Alzheimer's disease: effect on age at onset and relative risk in different age groups", J Neurol, 243, pp.452~456 (1996)
  59. Slooter AJ, "Risk estimates of dementia by apolipoprotein E genotypes from a population-based incidence study: the Rotterdam Study", Arch Neurol, 55, pp.964~968 (1998)
  60. Guerreiro RJ, "The genetic architecture of Alzheimer's disease: beyond APP, PSENs and APOE", Neurobiol Aging (2010)
  61. Strittmatter WJ, "Binding of human apolipoprotein E to synthetic amyloid beta peptide: isoform-specific effects and implications for late-onset Alzheimer disease", Proc Natl Acad Sci U S A, 90, pp.8098~8102 (1993)
  62. Strittmatter WJ, "Hypothesis: microtubule instability and paired helical filament formation in the Alzheimer disease brain are related to apolipoprotein E genotype", Exp Neurol, 125, pp.163~171 (1994)
  63. Namba Y, "Apolipoprotein E immunoreactivity in cerebral amyloid deposits and neurofibrillary tangles in Alzheimer's disease and kuru plaque amyloid in Creutzfeldt-Jakob disease", Brain Res, 541, pp.163~166 (1991)
  64. Sanan DA, "Apolipoprotein E associates with beta amyloid peptide of Alzheimer's disease to form novel monofibrils. Isoform apoE4 associates more efficiently than apoE3", J Clin Invest, 94, pp.860~869 (1994)
  65. Myers RH, "E epsilon4 association with dementia in a population-based study: the Framingham study", Neurology, 46, pp.673~677 (1996)
  66. Zannis VI, "Human apolipoprotein E isoprotein subclasses are genetically determined", Am J Hum Genet, 33, pp.11~24 (1981)
  67. Saunders AM, "Specificity, sensitivity, and predictive value of apolipoprotein-E genotyping for sporadic Alzheimer's disease", Lancet, 348, pp.90~93 (1996)
  68. Mayeux R, "Utility of the apolipoprotein E genotype in the diagnosis of Alzheimer's disease. Alzheimer's disease centers consortium on apolipoprotein E and Alzheimer's disease", N Engl J Med, 338, pp.506~511 (1998)
  69. Slooter AJ, "APOE genotyping in differential diagnosis of Alzheimer's disease", Lancet, 348, pp.334~ (1996)
  70. Kakulas BA, "Apolipoprotein-E genotyping in diagnosis of Alzheimer's disease", Lancet, 348, pp.483~ (1996)
  71. Tsuang D, "The utility of apolipoprotein E genotyping in the diagnosis of Alzheimer disease in a community-based case series", Arch Neurol, 56, pp.1489~1495 (1999)
  72. Farrer LA, "Apolipoprotein E genotype in patients with Alzheimer's disease: implications for the risk of dementia among relatives", Ann Neurol, 38, pp.797~808 (1995)
  73. de Silva HV, "A 70-kDa apolipoprotein designated ApoJ is a marker for subclasses of human plasma high density lipoproteins", J Biol Chem, 265, pp.13240~13247 (1990)
  74. May PC, "Dynamics of gene expression for a hippocampal glycoprotein elevated in Alzheimer's disease and in response to experimental lesions in rat", Neuron, 5, pp.831~839 (1990)
  75. Duguid JR, "Changes in brain gene expression shared by scrapie and Alzheimer disease", Proc Natl Acad Sci U S A, 86, pp.7260~7264 (1989)
  76. Oda T, "Purification and characterization of brain clusterin", Biochem Biophys Res Commun, 204, pp.1131~1136 (1994)
  77. Boggs LN, "Clusterin (Apo J) protects against in vitro amyloid-beta (1-40) neurotoxicity", J Neurochem, 67, pp.1324~1327 (1996)
  78. DeMattos RB, "Clusterin promotes amyloid plaque formation and is critical for neuritic toxicity in a mouse model of Alzheimer's disease", Proc Natl Acad Sci U S A, 99, pp.10843~10848 (2002)
  79. Matsubara E, "Apolipoprotein J and Alzheimer's amyloid beta solubility", Biochem J, 316, pp.671~679 (1996)
  80. Oda T, "Clusterin (apoJ) alters the aggregation of amyloid beta-peptide (A beta 1-42) and forms slowly sedimenting A beta complexes that cause oxidative stress", Exp Neurol, 136, pp.22~31 (1995)
  81. DeMattos RB, "ApoE and clusterin cooperatively suppress Abeta levels and deposition: evidence that ApoE regulates extracellular Abeta metabolism in vivo", Neuron, 41, pp.193~202 (2004)
  82. Bell RD, "Transport pathways for clearance of human Alzheimer's amyloid beta-peptide and apolipoproteins E and J in the mouse central nervous system", J Cereb Blood Flow Metab, 27, pp.909~918 (2007)
  83. Nuutinen T, "Clusterin: a forgotten player in Alzheimer's disease", Brain Res Rev, 61, pp.89~104 (2009)
  84. Bertrand P, "Association of apolipoprotein E genotype with brain levels of apolipoprotein E and apolipoprotein J (clusterin) in Alzheimer disease", Brain Res Mol Brain Res, 33, pp.174~178 (1995)
  85. Jun G, "Meta-analysis confirms CR1, CLU, and PICALM as alzheimer disease risk loci and reveals interactions with APOE genotypes", Arch Neurol, 67, pp.1473~1484 (2010)
  86. Corneveaux JJ, "Association of CR1, CLU and PICALM with Alzheimer's disease in a cohort of clinically characterized and neuropathologically verified individuals", Hum Mol Genet, 19, pp.3295~3301 (2010)
  87. Seshadri S, "Genome-wide analysis of genetic loci associated with Alzheimer disease", JAMA, 303, pp.1832~1840 (2010)
  88. Carrasquillo MM, "Replication of CLU, CR1, and PICALM associations with alzheimer disease", Arch Neurol, 67, pp.961~964 (2010)
  89. Thambisetty M, "Association of plasma clusterin concentration with severity, pathology, and progression in Alzheimer disease", Arch Gen Psychiatry, 67, pp.739~748 (2010)
  90. Nestlerode CS, "Apolipoprotein J polymorphisms and serum HDL cholesterol levels in African blacks", Hum Biol, 71, pp.197~218 (1999)
  91. Tebar F, "Clathrin assembly lymphoid myeloid leukemia (CALM) protein: localization in endocytic-coated pits, interactions with clathrin, and the impact of overexpression on clathrin-mediated traffic", Mol Biol Cell, 10, pp.2687~2702 (1999)
  92. Kim JA, "Cell-free expression and functional reconstitution of CALM in clathrin assembly", Exp Mol Med, 33, pp.89~94 (2001)
  93. Harel A, "Evidence for CALM in directing VAMP2 trafficking", Traffic, 9, pp.417~429 (2008)
  94. Pastor P, "Apolipoprotein Eepsilon4 modifies Alzheimer's disease onset in an E280A PS1 kindred", Ann Neurol, 54, pp.163~169 (2003)
  95. Wijsman EM, "APOE and other loci affect age-at-onset in Alzheimer's disease families with PS2 mutation", Am J Med Genet B Neuropsychiatr Genet, 132B, pp.14~20 (2005)
  96. St George-Hyslop P, "Alzheimer's disease and possible gene interaction", Science, 263, pp.357~ (1994)
  97. Biffi A, "Genetic variation and neuroimaging measures in Alzheimer disease", Arch Neurol, 67, pp.677~685 (2010)
  98. Baig S, "Distribution and expression of picalm in Alzheimer disease", J Neuropathol Exp Neurol, 69, pp.1071~1077 (2010)
  99. Kopec KK, "Alzheimer's beta-amyloid peptide 1-42 induces a phagocytic response in murine microglia", J Neurochem, 71, pp.2123~2131 (1998)
  100. Heneka MT, "Inflammatory processes in Alzheimer's disease", J Neuroimmunol, 184, pp.69~91 (2007)
  101. Tuppo EE, "The role of inflammation in Alzheimer's disease", Int J Biochem Cell Biol, 37, pp.289~305 (2005)
  102. Farfara D, "Neuroprotective and neurotoxic properties of glial cells in the pathogenesis of Alzheimer's disease", J Cell Mol Med, 12, pp.762~780 (2008)
  103. Sastre M, "Contribution of inflammatory processes to Alzheimer's disease: molecular mechanisms", Int J Dev Neurosci, 24, pp.167~176 (2006)
  104. Akiyama H, "Inflammation and Alzheimer's disease", Neurobiol Aging, 21, pp.383~421 (2000)
  105. Khera R, "Complement Receptor 1: disease associations and therapeutic implications", Mol Immunol, 46, pp.761~772 (2009)
  106. Kuo YM, "Amyloid-beta peptides interact with plasma proteins and erythrocytes: implications for their quantitation in plasma", Biochem Biophys Res Commun, 268, pp.750~756 (2000)
  107. Rogers J, "Peripheral clearance of amyloid beta peptide by complement C3-dependent adherence to erythrocytes", Neurobiol Aging, 27, pp.1733~1739 (2006)
  108. Webster S, "Aggregation state-dependent activation of the classical complement pathway by the amyloid beta peptide", J Neurochem, 69, pp.388~398 (1997)
  109. Wyss-Coray T, "Prominent neurodegeneration and increased plaque formation in complement-inhibited Alzheimer's mice", Proc Natl Acad Sci USA, 99, pp.10837~10842 (2002)
  110. Zhou J, "Complement C3 and C4 expression in C1q sufficient and deficient mouse models of Alzheimer's disease", J Neurochem, 106, pp.2080~2092 (2008)
  111. Sleegers K, "The pursuit of susceptibility genes for Alzheimer's disease: progress and prospects", Trends Genet, 26, pp.84~93 (2010)
  112. Motoi Y, "Neuronal localization of a novel mosaic apolipoprotein E receptor, LR11, in rat and human brain", Brain Res, 833, pp.209~215 (1999)
  113. Dodson SE, "LR11", SorLA expression is reduced in sporadic Alzheimer disease but not in familial Alzheimer disease, 2006, pp.65, 866~872
  114. Scherzer CR, "Loss of apolipoprotein E receptor LR11 in Alzheimer disease", Arch Neurol, 61, pp.1200~1205 (2004)
  115. Zhao Y, "Reduction of sortilin-1 in Alzheimer hippocampus and in cytokine-stressed human brain cells", Neuroreport, 18, pp.1187~1191 (2007)
  116. Andersen OM, "Neuronal sorting protein-related receptor sorLA", LR11 regulates processing of the amyloid precursor protein, 2005, pp.102, 13461~13466
  117. Offe K, "The lipoprotein receptor LR11 regulates amyloid beta production and amyloid precursor protein traffic in endosomal compartments", J Neurosci, 26, pp.1596~1603 (2006)
  118. Lee JH, "The association between genetic variants in SORL1 and Alzheimer disease in an urban, multiethnic, community-based cohort", Arch Neurol, 64, pp.501~506 (2007)
  119. Rogaeva E, "The neuronal sortilin-related receptor SORL1 is genetically associated with Alzheimer disease", Nat Genet, 39, pp.168~177 (2007)
  120. Bettens K, "SORL1 is genetically associated with increased risk for late-onset Alzheimer disease in the Belgian population", Hum Mutat, 29, pp.769~770 (2008)
  121. Lee JH, "Association between genetic variants in SORL1 and autopsy-confirmed Alzheimer disease", Neurology, 70, pp.887~889 (2008)
  122. Li Y, "SORL1 variants and risk of late-onset Alzheimer's disease", Neurobiol Dis, 29, pp.293~296 (2008)
  123. Meng Y, "Association between SORL1 and Alzheimer's disease in a genome-wide study", Neuroreport, 18, pp.1761~1764 (2007)
  124. Webster JA, "Sorl1 as an Alzheimer's disease predisposition gene", Neurodegener Dis, 5, pp.60~64 (2008)
  125. Feulner TM, "Examination of the current top candidate genes for AD in a genome-wide association study", Mol Psychiatry, 15, pp.756~766 (2010)
  126. Seshadri S, "Genetic correlates of brain aging on MRI and cognitive test measures: a genome-wide association and linkage analysis in the Framingham Study", BMC Med Genet, 8(Suppl 1), pp.S15~ (2007)
  127. Tan EK, "SORL1 haplotypes modulate risk of Alzheimer's disease in Chinese", Neurobiol Aging, 30, pp.1048~1051 (2009)
  128. Li H, "Candidate single-nucleotide polymorphisms from a genomewide association study of Alzheimer disease", Arch Neurol, 65, pp.45~53 (2008)
  129. Cartier L, "Chemokine receptors in the central nervous system: role in brain inflammation and neurodegenerative diseases", Brain Res Brain Res Rev, 48, pp.16~42 (2005)
  130. Szekely CA, "Non-steroidal anti-inflammatory drugs and Alzheimer's disease: the epidemiological evidence", CNS Neurol Disord Drug Targets, 9, pp.132~139 (2010)
  131. Lim GP, "Ibuprofen suppresses plaque pathology and inflammation in a mouse model for Alzheimer's disease", J Neurosci, 20, pp.5709~5714 (2000)
  132. Varvel NH, "NSAIDs prevent, but do not reverse, neuronal cell cycle reentry in a mouse model of Alzheimer disease", J Clin Invest, 119, pp.3692~3702 (2009)
  133. Saijo K, "A Nurr1", CoREST pathway in microglia and astrocytes protects dopaminergic neurons from inflammation-induced death, 2009, pp.137, 47~59
  134. Simi A, "Interleukin-1 and inflammatory neurodegeneration", Biochem Soc Trans, 35, pp.1122~1126 (2007)
  135. McCoy MK, "TNF signaling inhibition in the CNS: implications for normal brain function and neurodegenerative disease", J Neuroinflammation, 5, pp.45~ (2008)
  136. Alvarez V, "Association between the TNFalpha-308 A", G polymorphism and the onset-age of Alzheimer disease, 2002, pp.114, 574~577
  137. Culpan D, "Tumour necrosis factor-alpha gene polymorphisms and Alzheimer's disease", Neurosci Lett, 350, pp.61~65 (2003)
  138. Fung HC, "Heat shock protein 70 and tumor necrosis factor alpha in Taiwanese patients with dementia", Dement Geriatr Cogn Disord, 20, pp.1~7 (2005)
  139. Nishimura M, "Influence of polymorphisms in the genes for cytokines and glutathione S-transferase omega on sporadic Alzheimer's disease", Neurosci Lett, 368, pp.140~143 (2004)
  140. Perry RT, "Investigation of association of 13 polymorphisms in eight genes in southeastern African American Alzheimer disease patients as compared to age-matched controls", Am J Med Genet, 105, pp.335~342 (2001)
  141. Tedde A, "Lack of association between TNF-alpha polymorphisms and Alzheimer's disease in an Italian cohort", Neurosci Lett, 446, pp.139~142 (2008)
  142. Green EK, "Are interleukin-1 gene polymorphisms risk factors or disease modifiers in AD", Neurology, 58, pp.1566~1568 (2002)
  143. Minster RL, "Genetic association studies of interleukin-1 (IL-1A and IL-1B) and interleukin-1 receptor antagonist genes and the risk of Alzheimer's disease", Ann Neurol, 48, pp.817~819 (2000)
  144. Bosco P, "Association of IL-1 RN*2 allele and methionine synthase 2756 AA genotype with dementia severity of sporadic Alzheimer's disease", J Neurol Neurosurg Psychiatry, 75, pp.1036~1038 (2004)
  145. Ehl C, "Association of an interleukin-1beta gene polymor phism at position -511 with Alzheimer's disease", Int J Mol Med, 11, pp.235~238 (2003)
  146. Hedley R, "Association of interleukin-1 polymorphisms with Alzheimer's disease in Australia", Ann Neurol, 51, pp.795~797 (2002)
  147. Li XQ, "Interleukin-1 gene cluster polymorphisms and risk of Alzheimer's disease in Chinese Han population", J Neural Transm, 111, pp.1183~1190 (2004)
  148. Mattila KM, "Association of an interleukin 1B gene polymorphism (-511) with Parkinson's disease in Finnish patients", J Med Genet, 39, pp.400~402 (2002)
  149. McCulley MC, "Association between interleukin 1-beta promoter (-511) polymorphism and depressive symptoms in Alzheimer's disease", J Med Genet B Neuropsychiatr Genet, 124B, pp.50~53 (2004)
  150. Nicoll JA, "Association of interleukin-1 gene polymorphisms with Alzheimer's disease", Ann Neurol, 47, pp.365~368 (2000)
  151. Rosenmann H, "Lack of association of interleukin-1beta polymorphism with Alzheimer's disease in the Jewish population", Neurosci Lett, 363, pp.131~133 (2004)
  152. Sciacca FL, "Interleukin-1B polymorphism is associated with age at onset of Alzheimer's disease", Neurobiol Aging, 24, pp.927~931 (2003)
  153. Seripa D, "Genotypes and haplotypes in the IL-1 gene cluster: analysis of two genetically and diagnostically distinct groups of Alzheimer patients", Neurobiol Aging, 26, pp.455~464 (2005)
  154. Wang HK, "Interleukin-1alpha and -1beta promoter polymorphisms in Taiwanese patients with dementia", Dement Geriatr Cogn Disord, 24, pp.104~110 (2007)
  155. Wang WF, "Association of interleukin-1 beta and receptor antagonist gene polymorphisms with late onset Alzheimer's disease in Taiwan Chinese", Eur J Neurol, 12, pp.609~613 (2005)
  156. Wehr H, "Differences in risk factors for dementia with neurodegenerative traits and for vascular dementia", Dement Geriatr Cogn Disord, 22, pp.1~7 (2006)
  157. Yucesoy B, "Association of interleukin-1 gene polymorphisms with dementia in a community-based sample: the Honolulu-Asia Aging Study", Neurobiol Aging, 27, pp.211~217 (2006)
  158. Ma SL, "Lack of association of the interleukin-1beta gene polymorphism with Alzheimer's disease in a Chinese Population", Dement Geriatr Cogn Disord, 16, pp.265~268 (2003)
  159. Di Bona D, "Association between the interleukin- 1beta polymorphisms and Alzheimer's disease: a systematic review and meta-analysis", Brain Res Rev, 59, pp.155~163 (2008)
  160. Wang M, "Interleukin-6 receptor gene polymorphisms were associated with sporadic Alzheimer's disease in Chinese Han", Brain Res, 1324, pp.1~5 (2010)
  161. Capurso C, "Interleukin 6-174 G", C promoter gene polymorphism and sporadic Alzheimer's disease: geographic allele and genotype variations in Europe, 2004, pp.39, 1567~1573
  162. Ravaglia G, "Interleukin-1beta and interleukin-6 gene polymorphisms as risk factors for AD: a prospective study", Exp Gerontol, 41, pp.85~92 (2006)
  163. Koivisto AM, "Interleukin-6 promoter polymorphism and late-onset Alzheimer's disease in the Finnish population", J Neurogenet, 19, pp.155~161 (2005)
  164. van Oijen M, "Polymorphisms in the interleukin 6 and transforming growth factor beta1 gene and risk of dementia. The Rotterdam Study", Neurosci Lett, 402, pp.113~117 (2006)
  165. Paradowski B, "Polymorphism 174 G", C of interleukin 6 gene in Alzheimer's disease-preliminary report, 2008, pp.42, 312~315
  166. Capurso C, "Interleukin 6-174 G", C promoter and variable number of tandem repeats (VNTR) gene polymorphisms in sporadic Alzheimer's disease, 2010, pp.34, 177~182
  167. He MX, "Association between interleukin-6 gene promoter -572C", G polymorphism and the risk of sporadic Alzheimer's disease, 2010, pp.31, 165~168
  168. Infante J, "Gene-gene interaction between interleukin- 6 and interleukin-10 reduces AD risk", Neurology, 63, pp.1135~1136 (2004)
  169. Combarros O, "Replication by the Epistasis Project of the interaction between the genes for IL-6 and IL-10 in the risk of Alzheimer's disease", J Neuroinflammation, 6, pp.22~ (2009)
  170. Vural P, "The combinations of TNFalpha-308 and IL-6 -174 or IL-10 -1082 genes polymorphisms suggest an association with susceptibility to sporadic late-onset Alzheimer's disease", Acta Neurol Scand, 120, pp.396~401 (2009)
  171. Arosio B, "Interleukin-10 and interleukin-6 gene polymorphisms as risk factors for Alzheimer's disease", Neurobiol Aging, 25, pp.1009~1015 (2004)
  172. Bagnoli S, "Association of IL10 promoter polymorphism in Italian Alzheimer's disease", Neurosci Lett, 418, pp.262~265 (2007)
  173. Lio D, "Interleukin-10 promoter polymorphism in sporadic Alzheimer's disease", Genes Immun, 4, pp.234~238 (2003)
  174. Scassellati C, "Promoter haplotypes of interleukin-10 gene and sporadic Alzheimer's disease", Neurosci Lett, 356, pp.119~122 (2004)
  175. Ma SL, "The association between promoter polymorphism of the interleukin-10 gene and Alzheimer's disease", Neurobiol Aging, 26, pp.1005~1010 (2005)
  176. Giedraitis V, "Genetic analysis of Alzheimer's disease in the Uppsala Longitudinal Study of Adult Men", Dement Geriatr Cogn Disord, 27, pp.59~68 (2009)
  177. Depboylu C, "of association of interleukin- 10 promoter region polymorphisms with Alzheimer's disease", Neurosci Lett, 342, pp.132~134 (2003)
  178. Cousin E, "No replication of genetic association between candidate polymorphisms and Alzheimer's disease", Neurobiol Aging, 32, pp.1443~1451 (2011)
  179. Candore G, "Polymorphisms of pro-inflammatory genes and Alzheimer's disease risk: a pharmacogenomic approach", Mech Ageing Dev, 128, pp.67~75 (2007)
  180. Arosio B, "Intereleukin- 10 promoter polymorphism in mild cognitive impairment and in its clinical evolution", Int J Alzheimers Dis, 2010 (2010)
  181. Ma SL, "Association of prostaglandin-endoperoxide synthase 2 (PTGS2) polymorphisms and Alzheimer's disease in Chinese", Neurobiol Aging, 29, pp.856~860 (2008)
  182. Listi F, "Role of cyclooxygenase-2 and 5-lipoxygenase polymorphisms in Alzheimer's disease in a population from northern Italy: implication for pharmacogenomics", J Alzheimers Dis, 19, pp.551~557 (2010)
  183. Abdullah L, "The cyclooxygenase 2-765 C promoter allele is a protective factor for Alzheimer's disease", Neurosci Lett, 395, pp.240~243 (2006)
  184. Choi JK, "Anti-inflammatory treatment in AD mice protects against neuronal pathology", Exp Neurol, 223, pp.377~384 (2010)
  185. Nivsarkar M, "Cyclooxygenase inhibitors: a novel direction for Alzheimer's management", Pharmacol Rep, 60, pp.692~698 (2008)
  186. Ioannidis JP, "Implications of small effect sizes of individual genetic variants on the design and interpretation of genetic association studies of complex diseases", Am J Epidemiol, 164, pp.609~614 (2006)
  187. Evans DM, "Harnessing the information contained within genome-wide association studies to improve individual prediction of complex disease risk", Hum Mol Genet, 18, pp.3525~3531 (2009)
  188. Lango H, "Assessing the combined impact of 18 common genetic variants of modest effect sizes on type 2 diabetes risk", Diabetes, 57, pp.3129~3135 (2008)
  189. Khoury MJ, "An epidemiologic assessment of genomic profiling for measuring susceptibility to common diseases and targeting interventions", Genet Med, 6, pp.38~47 (2004)
  190. Grupe A, "Evidence for novel susceptibility genes for late-onset Alzheimer's disease from a genome-wide association study of putative functional variants", Hum Mol Genet, 16, pp.865~873 (2007)
  191. Abraham R, "A genome-wide association study for late-onset Alzheimer's disease using DNA pooling", BMC Med Genomics, 1, pp.44~ (2008)
  192. Bertram L, "Genome-wide association analysis reveals putative Alzheimer's disease susceptibility loci in addition to APOE", Am J Hum Genet, 83, pp.623~632 (2008)
  193. Beecham GW, "Genome-wide association study implicates a chromosome 12 risk locus for late-onset Alzheimer disease", Am J Hum Genet, 84, pp.35~43 (2009)
  194. Feulner TM, "Examination of the current top candidate genes for AD in a genome-wide association study", Mol Psychiatry, 15, pp.756~766 (2010)

관련 논문AI추천

Blood Biomarkers for Alzheimer’s Dementia DiagnosisChang-Eun Park대한임상검사과학회 · 대한임상검사과학회지2022 · 제54권 제4호Biomarkers Predicting Alzheimer’s Disease in Cognitively Normal Aging심용수, John C. Morris대한신경과학회 · Journal of Clinical Neurology2011 · 제7권 제2호Genetics of Alzheimer's Disease김종헌대한치매학회 · Dementia and Neurocognitive Disorders(대한치매학회지)2018 · 제17권 제4호Current Challenges for the Early Detection of Alzheimer’s Disease: Brain Imaging and CSF StudiesLisa Mosconi, Marla Guzman, Mony J. de Leon, Rachel Mistur, Susan De Santi, Wai Tsui, Yi Li대한신경과학회 · Journal of Clinical Neurology2009 · 제5권 제4호Impact of Apolipoprotein E ε4 in Alzheimer’s Disease: Insights From a Meta-Analysis고성호, Hyuk Sung Kwon대한신경과학회 · Journal of Clinical Neurology2024 · 제20권 제5호Promising Blood Biomarkers for Clinical Use in Alzheimer’s Disease: A Focused Update김민경, 문소영, 박선아, 이선민, 장유정대한신경과학회 · Journal of Clinical Neurology2022 · 제18권 제4호

이 간행물의 다른 논문 (6건)

Second-Generation Antipsychotic Discontinuation in First Episode Psychosis: An Updated ReviewKrystle Crittenden, Brian J. Miller, Chelsea Bodenheimerpp. 45-53Rapid Changes in D1 and D2 Dopamine Receptor Binding in Striatal Subregions after a Single Dose of PhencyclidineKaterina Zavitsanou, Victoria S. Daltonpp. 67-72The Tolerability of Mirtazapine Augmentation in Schizophrenic Patients Treated with Risperidone: A Preliminary Randomized Placebo-controlled TrialKeunyoung Yook, Sungjae Lee, Keung-Hyang Kim, Tae Kyou Choi, 김보라, 최아영, 이상혁, Sung Joon Cho, Kang Soo Lee, Jieun Leepp. 73-77Effects of Psychotropic Drugs on Quantitative EEG among Patients with Schizophrenia-spectrum Disorders백명재, 강웅구, 현준pp. 78-85Effects of Sinapic Acid of 4 Vessel Occlusion Model-Induced Ischemia and Cognitive Impairments in the RatYoung Ock Kim, Hee Jae Lee, Sang-Won Lee, 오명숙pp. 86-90
원문 보기